Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy subject of either gender of 9 months of age~2. Negative clinical history of measles, mumps, rubella, varicella or zoster~3. Informed consent form signed by both parents or legal representative~4. Parent(s) or legal representative able to attend all the scheduled visits with the subject and to understand and comply with the study procedures~5. Both parent or legal representative are over 18 years of age~6. Subject is affiliated to a health social security system~Exclusion Criteria:~1. Febrile illness in the previous 3 days~2. Prior vaccination with a measles, mumps, rubella and/or varicella vaccine either alone or in any combination~3. Exposure to measles, mumps, rubella, varicella and/or zoster in the previous 30 days~4. Tuberculin test done in the previous 2 days~5. Severe chronic disease~6. Known active tuberculosis~7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition~8. Hereditary problems of fructose intolerance~9. Prior known sensitivity or allergy to any component of the vaccine~10. Known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems~11. Humoral or cellular immunodeficiency,~12. Immunosuppressive therapy \[including systemic corticosteroids (a), given daily or on alternate days at high doses (\>=2 mg/kg/day prednisone equivalent or \>=20 mg/day if the subject's weight was \>10 kg) during at least 14 days in the previous 30 days\]~13. Family history of congenital or hereditary immunodeficiency~14. Receipt of immunoglobulins or blood-derived products in the previous 150 days or scheduled to be administered through Visit 5~15. Receipt of an inactivated vaccine in the previous 14 days~16. Receipt of a live non-study vaccine in the previous 28 days~17. Any medical condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives~18. Current participation or scheduled participation in any other clinical study through Visit 5

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1: ProQuad® at 9 and 12 months (Type: EXPERIMENTAL): Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.
- Arm 2: ProQuad® at 11 and 14 months (Type: EXPERIMENTAL): Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.
- Arm 3: ProQuad at 12 and 15 months (Type: ACTIVE_COMPARATOR): Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).